Participant flow

Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer · Source last updated 2012-09-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cisplatin, Starting dose 30 mg/m2 Dose level -1 20 mg/m2; Irinotecan, Starting Dose 50 mg/m2, Dose level -1 40 mg/m2

   id

   FG000

   title

   Therapeutic Intervention

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Lack of Efficacy

   4. reasons

      1. group Id

         FG000

         num Subjects

         26

      type

      Disease progression

   5. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total of 41 people signed consent to take part in this study, of those, 1 was determined to be ineligible.

recruitment Details

Recruitment period = 2/27/2002 through 5/9/2006

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice